Allurion Technologies, Inc.

Allurion Technologies is a medical device company specializing in non-surgical weight-loss solutions for obesity management. The company's flagship product, the Allurion Balloon, is a swallowable gastric balloon that occupies stomach space to promote satiety and reduce food intake. Clinical evidence demonstrates that patients achieve an average weight loss of 10–15% of total body weight within four months. The Allurion Program combines the procedureless balloon with a comprehensive digital ecosystem featuring the Allurion Virtual Care Suite, an AI-powered mobile app (Coach Iris), connected smart scale, and multidisciplinary support from dieticians, doctors, and behavior change specialists. The program runs for a minimum of six months and emphasizes metabolically healthy weight loss—preserving lean muscle mass while reducing fat. The device is CE-marked and available globally through accredited clinic partners; it is not currently FDA-approved in the United States. Allurion has served over 180,000 patients worldwide and is publicly traded on the NYSE under ticker ALUR.